followers 4 popularity
following 1

followers  view all

following  view all

tarunc is not in any groups

Global Graft Versus Host Disease (GVHD) Treatment Market Forecast 2018-2025 : Abbott, Caladrius, Eli Lilly, Glenmark

Jan 3rd 2019 at 3:48 AM

This report studies the global Graft Versus Host Disease (GVHD) Treatment market size, industry status and forecast, competition landscape and growth opportunity. This research report categorizes the global Graft Versus Host Disease (GVHD) Treatment market by companies, region, type and end-use industry.

Graft versus Host disease occurs after a stem cell or bone marrow transplant. High dose treatment destroy cancer cells along with that it simultaneously destroys healthy cells. Stem cell and bone marrow transplant treatments are used in reconstructing damaged cells, surrounding cancer tumors. Normally after high dose treatment, patient receives bone marrow from a donor through drip which resumes production of blood cells. Graft versus Host Disease occurs when certain types of white blood cells. This is caused due to the transplanted cells (graft) see recipients body (host) as exotic, thus transplanted cells attack the host body.

Have Any Query? Ask Our Expert @

The growing number of organ transplantation cases as one of the major factors that will have a positive impact on the growth of the market. The rise in chronic diseases across the globe has led to the growth in the need for organ transplantation. It has been observed that in 2015, the US witnessed more than 30,000 organ transplants cases, which has increased about 5% when compared to the previous year. Similarly, countries such as Australia also witnesses increasing cases of organ transplantation. This rising number of organ transplants will subsequently augment the growth prospects of the GVHD treatment market.

The Americas is expected to be the major revenue contributor to the GVHD treatment market by 2021. The increasing number of transplantation procedures and the growing healthcare infrastructure, will fuel the growth prospects of the market in this region. Moreover, the increasing cases of organ failures due to the unhealthy lifestyle and dietary habits of the people and the approvals of new drugs for the treatment of GVHD, will also drive the markets growth in this region.

In 2017, the global Graft Versus Host Disease (GVHD) Treatment market size was xx million US$ and it is expected to reach xx million US$ by the end of 2025, with a CAGR of xx% during 2018-2025.

This report focuses on the global top players, covered
Bristol-Myers Squibb
Astellas Pharma
Eli Lilly
Kadmon Holdings
Osiris Therapeutics

Market segment by Regions/Countries, this report covers
United States
Southeast Asia

Browse Press Release of this Research Report:

Market segment by Type, the product can be split into
Monoclonal Antibodies
MTOR Inhibitors
Tyrosine Kinase Inhibitors

Market segment by Application, split into
Acute Graft Versus Host Disease (aGvHD)
Chronic Graft Versus Host Disease (cGvHD)

The study objectives of this report are:
To study and forecast the market size of Graft Versus Host Disease (GVHD) Treatment in global market.
To analyze the global key players, SWOT analysis, value and global market share for top players.
To define, describe and forecast the market by type, end use and region.
To analyze and compare the market status and forecast between China and major regions, namely, United States, Europe, China, Japan, Southeast Asia, India and Rest of World.
To analyze the global key regions market potential and advantage, opportunity and challenge, restraints and risks.
To identify significant trends and factors driving or inhibiting the market growth.
To analyze the opportunities in the market for stakeholders by identifying the high growth segments.
To strategically analyze each submarket with respect to individual growth trend and their contribution to the market
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market
To strategically profile the key players and comprehensively analyze their growth strategies.

In this study, the years considered to estimate the market size of Graft Versus Host Disease (GVHD) Treatment are as follows:
History Year: 2013-2017
Base Year: 2017
Estimated Year: 2018
Forecast Year 2018 to 2025

For the data information by region, company, type and application, 2017 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

Key Stakeholders

Graft Versus Host Disease (GVHD) Treatment Manufacturers
Graft Versus Host Disease (GVHD) Treatment Distributors/Traders/Wholesalers
Graft Versus Host Disease (GVHD) Treatment Subcomponent Manufacturers
Industry Association
Downstream Vendors

Regional and country-level analysis of the Graft Versus Host Disease (GVHD) Treatment market, by end-use.
Detailed analysis and profiles of additional market players.

About Us: delivers the latest strategic market intelligence to build a successful business footprint in China. Our syndicated and customized research reports provide companies with vital background information of the market and in-depth analysis on the Chinese trade and investment framework, which directly affects their business operations. Reports from feature valuable recommendations on how to navigate in the extremely unpredictable yet highly attractive Chinese market.

Contact Us:

Brooklyn, NY 11230
United States
Toll Free: 866-997-4948 (USA-CANADA)
Tel: +1-518-621-2074
Follow Us on LinkedIn:
Blog –

Please to comment

sign in

Remember Me

New to IM faceplate? join free!

Lost Password? click here